Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model.
Endothelial monocyte-activating polypeptide-II (EMAP-II) is a novel proinflammatory cytokine with anti-angiogenic properties. The aim of this work was to evaluate in vivo antitumor activity of EMAP-II in growing human prostate adenocarcinoma xenograft mouse model.


METHODS
Recombinant human EMAP-II was expressed in Escherichia coli and purified after cleavage with enterokinase (EMAP-II e). EMAP-II preparations were injected to CBA mice bearing subrenal capsule xenografts of human prostate adenocarcinoma. After 3-days treatment, the xenografts were isolated and weighed, then the transplants exposed to EMAP II e (100 or 200 microg/kg b. w.) were examined histologically.


RESULTS
EMAP-II administered daily at a dose of 100 or 200 microg/kg b. w. caused striking retardation of local tumor progression as compared to the controls. Low dose (10 microg/kg) was effective in some cases.


CONCLUSIONS
EMAP II exhibits significant antitumor activity in vivo in human prostate adenocarcinoma xenografts in mouse model.
Reznikov
A G
AG
VP Komisarenko Institute of Endocrinology and Metabolism, Academy of Medical Sciences of Ukraine, Kyiv, Ukraine. dccie@mail.kar.net
Chaykovskaya
L V
LV
Polyakova
L I
LI
Kornelyuk
A I
AI
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D016207:Cytokines / Q000494:pharmacology*; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009363:Neoplasm Proteins / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016601:RNA-Binding Proteins / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D016207:Cytokines; D009363:Neoplasm Proteins; D016601:RNA-Binding Proteins; D011994:Recombinant Proteins; C077219:small inducible cytokine subfamily E, member 1